Alexis B. Cortot - Concepedia

Author

Alexis B. Cortot

Centre Hospitalier Universitaire de Lille ORCID

Also Known As

A Cortot, A. Cortot, A.-B. Cortot, A.B. Cortot, AB Cortot, Alexis B Cortot, Alexis B. Cortot, Alexis Benjamin Cortot, Alexis CORTOT, Alexis Cortot

496

Publications

11.2K

Citations

H-Index

105

Concepts

All Affiliations

Centre Hospitalier Universitaire de Lille Université de Lille Inserm Centre National de la Recherche Scientifique Institut Gustave Roussy

About

Alexis B. Cortot is an author at Centre Hospitalier Universitaire de Lille specializing in medicine, lung cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	51	6.7K
2	Health Sciences	9	9	1.5K
3	Nursing	3	3	80
4	Engineering	2	2	41
5	Public Health	2	2	40

Alexis B. Cortot

Publications

9.9K

Citations

H-Index

Page 1

	Year	Citations
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry J. Mazieres, Alexander Drilon, Amélie Lusque, Annals of Oncology Advanced Lung CancerCancer ImmunosurveillanceMedicineImmune Checkpoint InhibitorsImmunology	2019	1.3K
First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study Jean‐Charles Soria, Daniel S.W. Tan, Rita Chiari, The Lancet MedicineBronchial NeoplasmAdvanced AlkFirst-line CeritinibCancer Treatment	2017	1.1K
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M Wenjun Zhou, Dalia Ercan, Liang Chen, Nature Egfr T790mMedicineReceptor Tyrosine KinasePharmacologyTumor Biology	2009	988
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations Paul K. Paik, Enriqueta Felip, Rémi Veillon, New England Journal of Medicine	2020	819
Lung Cancer That Harbors an <i>HER2</i> Mutation: Epidemiologic Characteristics and Therapeutic Perspectives Julien Mazières, Solange Peters, Benoît Lepage, Journal of Clinical Oncology	2013	651
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial Kazuhiko Nakagawa, Edward B. Garon, Takashi Seto, The Lancet Oncology MedicinePathologyImmune Checkpoint InhibitorCancer TreatmentOncology	2019	594
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study Antonio Passaro, Jing Wang, Yan Wang, Annals of Oncology	2023	347
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort Julien Mazières, Fabrice Barlési, Thomas Filleron, Annals of Oncology MedicinePathologyHer2-targeted DrugsBronchial NeoplasmEuropean Euher2 Cohort	2015	320
Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis M. Duruisseaux, Anna Martínez‐Cardús, María Eréndira Calleja-Cervantes, The Lancet Respiratory Medicine Anti-pd-1 TreatmentMedicineRetrospective AnalysisCancer GenomicsBronchial Neoplasm	2018	214
Crizotinib in c-MET- or ROS1-positive NSCLC: results of the AcSé phase II trial Denis Moro‐Sibilot, Nathalie Cozic, M. Pérol, Annals of Oncology Medicinal ChemistryRos1-positive NsclcMedicineClinical TrialsPharmacotherapy	2019	192

Page 1